Vincent V G An1, Kevin Phan1, Yadin D Levy2, Warwick J M Bruce3. 1. Faculty of Medicine, Sydney Medical School, University of Sydney, New South Wales, Australia. 2. Department of Orthopaedic Surgery, Concord Repatriation General Hospital, New South Wales, Australia. 3. Faculty of Medicine, Sydney Medical School, University of Sydney, New South Wales, Australia; Department of Orthopaedic Surgery, Concord Repatriation General Hospital, New South Wales, Australia.
Abstract
BACKGROUND: Venous thromboembolism (VTE) comprises pulmonary embolism and deep vein thrombosis and is a complication of particular concern in lower limb arthroplasty. In recent years, aspirin has emerged as a potential alternative thromboprophylactic agent, particularly after its acceptance as a recommended agent by the American College of Chest Physicians. Aspirin is favorable due to its relative cost-effectiveness and convenience compared to novel oral anticoagulants and warfarin. However, its efficacy since its inclusion in the American College of Chest Physicians guidelines remains unclear. The present systematic review aimed to establish the efficacy of aspirin in preventing VTE in total hip and knee arthroplasty. METHODS: Electronic searches were performed using 6 databases from up to June 2015, identifying all relevant studies. Data were extracted and meta-analyzed. RESULTS: Eleven relevant studies were identified for inclusion in the present meta-analysis. The overall rate of deep vein thrombosis and pulmonary embolism in both hip and knee arthroplasty was 1.2% and 0.6%, respectively. The rate of major bleeding was 0.3%. Pooled mortality rate was 0.2%. All findings demonstrated a high and significant degree of heterogeneity. CONCLUSION: Aspirin, both alone and in multimodal approaches to thromboprophylaxis, confers a low rate of VTE, with a low risk of major bleeding complications. However, the evidence for its use is limited by the low quality of studies and variation in dose in dosing regimes. Future randomized controlled trials should investigate the efficacy of aspirin, as well as the ideal dosing protocol for its use in thromboprophylaxis in arthroplasty.
BACKGROUND:Venous thromboembolism (VTE) comprises pulmonary embolism and deep vein thrombosis and is a complication of particular concern in lower limb arthroplasty. In recent years, aspirin has emerged as a potential alternative thromboprophylactic agent, particularly after its acceptance as a recommended agent by the American College of Chest Physicians. Aspirin is favorable due to its relative cost-effectiveness and convenience compared to novel oral anticoagulants and warfarin. However, its efficacy since its inclusion in the American College of Chest Physicians guidelines remains unclear. The present systematic review aimed to establish the efficacy of aspirin in preventing VTE in total hip and knee arthroplasty. METHODS: Electronic searches were performed using 6 databases from up to June 2015, identifying all relevant studies. Data were extracted and meta-analyzed. RESULTS: Eleven relevant studies were identified for inclusion in the present meta-analysis. The overall rate of deep vein thrombosis and pulmonary embolism in both hip and knee arthroplasty was 1.2% and 0.6%, respectively. The rate of major bleeding was 0.3%. Pooled mortality rate was 0.2%. All findings demonstrated a high and significant degree of heterogeneity. CONCLUSION:Aspirin, both alone and in multimodal approaches to thromboprophylaxis, confers a low rate of VTE, with a low risk of major bleeding complications. However, the evidence for its use is limited by the low quality of studies and variation in dose in dosing regimes. Future randomized controlled trials should investigate the efficacy of aspirin, as well as the ideal dosing protocol for its use in thromboprophylaxis in arthroplasty.
Authors: Mhamad Faour; Nicolas S Piuzzi; David P Brigati; Alison K Klika; Michael A Mont; Wael K Barsoum; Carlos A Higuera Journal: Clin Orthop Relat Res Date: 2019-02 Impact factor: 4.176
Authors: Verinder S Sidhu; Thu-Lan Kelly; Nicole Pratt; Stephen E Graves; Rachelle Buchbinder; Sam Adie; Kara Cashman; Ilana Ackerman; Durga Bastiras; Roger Brighton; Alexander W R Burns; Beng Hock Chong; Ornella Clavisi; Maggie Cripps; Mark Dekkers; Richard de Steiger; Michael Dixon; Andrew Ellis; Elizabeth C Griffith; David Hale; Amber Hansen; Anthony Harris; Raphael Hau; Mark Horsley; Dugal James; Omar Khorshid; Leonard Kuo; Peter Lewis; David Lieu; Michelle Lorimer; Samuel MacDessi; Peter McCombe; Catherine McDougall; Jonathan Mulford; Justine Maree Naylor; Richard S Page; John Radovanovic; Michael Solomon; Rami Sorial; Peter Summersell; Phong Tran; William L Walter; Steve Webb; Chris Wilson; David Wysocki; Ian A Harris Journal: JAMA Date: 2022-08-23 Impact factor: 157.335
Authors: Abiram Bala; James I Huddleston; Stuart B Goodman; William J Maloney; Derek F Amanatullah Journal: Clin Orthop Relat Res Date: 2017-05-31 Impact factor: 4.176
Authors: Brandon R Hood; Mark E Cowen; Huiyong T Zheng; Richard E Hughes; Bonita Singal; Brian R Hallstrom Journal: JAMA Surg Date: 2019-01-01 Impact factor: 14.766